European Addiction Research

Vorberg F.a· Reimer J.a,b· Verthein U.a

Author affiliations

aCentre for Interdisciplinary Addiction Research (ZIS), University Medical Centre Hamburg-Eppendorf, Department of Psychiatry and Psychotherapy, Hamburg, Germany
bCentre for Psychosocial Medicine, Clinic Itzehoe, Itzehoe, Germany

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: May 06, 2022
Accepted: October 11, 2022
Published online: December 19, 2022

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 5

ISSN: 1022-6877 (Print)
eISSN: 1421-9891 (Online)

For additional information: https://www.karger.com/EAR

Abstract

Introduction: After rapidly opening up a low-threshold clinic to support heavily opioid-dependent persons at the beginning of the COVID-19 pandemic in April 2020 in Hamburg (Germany), this non-interventional study evaluated the feasibility and short-term effects of opioid substitution treatment (OST). The low-threshold concept was customized for the pandemic situation and is the first of its kind in Germany. Methods: Patients who had already begun treatment were questioned in two assessments, at T1 shortly after beginning treatment and at T2 6 months later. The primary outcome criterion was their quality of life using the OSTQOL. Secondary criteria included retention rate, their mental and physical health (measured by the BSI-18 and the OTI Health Scale), social situation, drug use, COVID-19 status, and satisfaction with treatment. Results: Out of 84 patients included in the study, 51 participated in both assessments, resulting in a 6-month retention rate of 60.7%. 27.5% were females, and 72.5% were males. The feasibility question of the low-threshold OST clinic can clearly be answered positively. During the course of the study over 6 months, the situation mainly remained stable regarding quality of life, physical and mental health, and days of drug consumption. Patients significantly reduced the time they spent on the drug scene from 8.5 (SD = 7.56) to 6.1 (SD = 6.71) hours a day between the beginning of OST and T2 (p = 0.020). While 56.9% answered to be homeless at the beginning of OST, only 33.3% answered not to have found an accommodation by T2 (p = 0.012). The number of patients having contact to social workers increased from 51.0% to 74.5% (p = 0.004). Almost 2 fifths of the patients took part in PCR testing for COVID-19 (that only being done if they had symptoms), and none of the tests were positive. Discussion/Conclusions: Overall, the low-threshold OST clinic has been successfully implemented in order to help a vulnerable group of people navigate through a global pandemic and support the public health sector. Further conclusions on effects are limited by the short study period and the small number of patients, which calls for further research studies in a larger setting.

© 2022 S. Karger AG, Basel

References Ornell F, Moura HF, Scherer JN, Pechansky F, Kessler FHP, von Diemen L. The COVID-19 pandemic and its impact on substance use: implications for prevention and treatment. Psychiatry Res. 2020;289:113096. Van den Brink W, Haasen C. Evidence-based treatment of opioid-dependent patients. Can J Psychiatry. 2006 Sep;51(10):635–46. German Ministry of Health. Annual report on addiction. Berlin, Germany: BMG-D-11056; 2021 Aug. Kourounis G, Richards BDW, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016 Apr;161:1–8. Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015 Feb;12(1):12. Hall NY, Le L, Majmudar I, Mihalopoulos C. Barriers to accessing opioid substitution treatment for opioid use disorder: a systematic review from the client perspective. Drug Alcohol Depend. 20212021;221:108651. Ayres R, Ingram J, Rees A, Neale J, Beattie A, Telfer M. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study. Subst Abuse Treat Prev Pol. 2014 Nov;9:44. Nolan S, Hayashi K, Milloy MJ, Kerr T, Dong H, Lima VD, et al. The impact of low-threshold methadone maintenance treatment on mortality in a Canadian setting. Drug Alcohol Depend. 2015 Nov;156:57–61. Parsons D, Burrows D, Bolotbaeva A. Advocating for opioid substitution therapy in Central Asia: much still to be done. Int J Drug Pol. 2014;25(6):1174–7. Marks M, Scheibe A, Shelly S. High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion. Harm Reduct J. 2020;17(1):25. Harm Reduction International [Internet, 2019]. The state of harm reduction in Western Europe 2018 [cited 2022 April 5]. Available from: https://www.hri.global/files/2019/05/20/harm-reduction-western-europe-2018.pdf. Horyniak D, Higgs P, Jenkinson R, Degenhardt L, Stoové M, Kerr T, et al. Establishing the melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. Harm reduction J. 2013;10(1):11. Jakubowski A, Fox A. Defining low-threshold buprenorphine treatment. J Addict Med. 2020;14(2):95–8. Johnson B, Richert T. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduct J. 2019;16(1):31. Duncan DF, Nicholson T, Clifford P, Hawkins W, Petosa R. Harm reduction: an emerging new paradigm for drug education. J Drug Educ. 1994;24(4):281–90. Kapadia SN, Griffin JL, Waldman J, Ziebarth NR, Schackman BR, Behrends CN. A harm reduction approach to treating opioid use disorder in an independent primary care practice: a qualitative study. J Gen Intern Med. 2021;36(7):1898–905. German Ministry of Health. Verordnung über Abweichungen von den Vorschriften des Fünften Buches Sozialgesetzbuch, des Apothekengesetzes, der Apothekenbetriebsordnung, der Arzneimittelpreisverordnung, des Betäubungsmittelgesetzes und der Betäubungsmittel-Verschreibungsverordnung infolge der SARS-CoV-2-Epidemie [Regulation of deviations of the German Narcotics Prescription Law as a result of the COVID-19 pandemic]. Berlin, Germany; 2020. Strada L, Franke GH, Schulte B, Reimer J, Verthein U. Development of OSTQOL: a measure of quality of life for patients in opioid substitution treatment. Eur Addict Res. 2017 Nov;23(5):238–48. Spitzer C, Hammer S, Löwe B, Grabe HJ, Barnow S, Rose M, et al. [The short version of the Brief Symptom Inventory (BSI -18): preliminary psychometric properties of the German translation]. Fortschr Neurol Psychiatr. 2011 Sep;79:517–23. Darke S, Hall W, Wodaki A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Addiction. 1992 May;87(5):733–42. O’Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020 May;15(5):e0232086. Lambert DG. Opioids and the COVID-19 pandemic: does chronic opioid use or misuse increase clinical vulnerability? Br J Anaesth. 2020;125(4):e382–3. Eagleton M, Stokes S, Fenton F, Keenan E. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3. Br J Anaesth. 2021;126(3):e114–6. Tahamtan A, Tavakoli-Yaraki M, Salimi V. Opioids/cannabinoids as a potential therapeutic approach in COVID-19 patients. Expert Rev Respir Med. 2020;14(10):965–7. New York City Department of Health and Mental Hygiene. Cocaine: do you have a problem? Health Bull Volume 10, Number 6. New York City, New York, USA; 2011. Government of the United Kingdom [Internet, 2021]. Introducing Opioid Substitution Treatment (OST) [cited 2022 August 7]. Available from: https://www.gov.uk/government/publications/opioid-substitution-treatment-guide-for-keyworkers/part-1-introducing-opioid-substitution-treatment-ost. Article / Publication Details

First-Page Preview

Received: May 06, 2022
Accepted: October 11, 2022
Published online: December 19, 2022

Number of Print Pages: 8
Number of Figures: 0
Number of Tables: 5

ISSN: 1022-6877 (Print)
eISSN: 1421-9891 (Online)

For additional information: https://www.karger.com/EAR

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.